Edison issues outlook on Carbios (ALCRB)
October 15, 2018 08:33 ET
|
Edison Investment Research Limited
LONDON, Oct. 15, 2018 (GLOBE NEWSWIRE) -- H118 results were broadly in line with our expectations and Carbios (ALCRB) retains sufficient cash to finance its business until H219. The company...
Edison issues update on Quantum Genomics (ALQGC)
October 09, 2018 07:43 ET
|
Edison Investment Research Limited
LONDON, Oct. 09, 2018 (GLOBE NEWSWIRE) -- Quantum Genomics (ALQGC) has announced that the results of its Phase IIb NEW-HOPE study will be presented in a late-breaking presentation at the American...
Edison issues outlook on NeuroVive Pharmaceutical (NVP)
October 05, 2018 06:37 ET
|
Edison Investment Research Limited
LONDON, Oct. 05, 2018 (GLOBE NEWSWIRE) -- On 18 June 2018, NeuroVive (NVP:SS) announced that it had out-licensed a subset of compounds from its NVP015 programme (succinate prodrugs) to BridgeBio, a...
Edison issues update on Immutep (IMMX)
September 27, 2018 04:36 ET
|
Edison Investment Research Limited
LONDON, Sept. 27, 2018 (GLOBE NEWSWIRE) -- Immutep (IMM:ASE) has entered into a clinical trial collaboration and supply agreement with Merck/Pfizer to investigate the combination of its APC...
Edison issues initiation on Brighter (BRIG)
September 25, 2018 08:52 ET
|
Edison Investment Research Limited
LONDON, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Brighter (BRIG:SS) is a healthtech company developing solutions for chronic diseases. Its initial strategy is the launch of Actiste, a mobile-connected...
Edison issues outlook on TransContainer (TRCN)
September 25, 2018 08:48 ET
|
Edison Investment Research Limited
LONDON, Sept. 25, 2018 (GLOBE NEWSWIRE) -- TransContainer (TRCN:RM) has continued to show strong results, with Q218 EBITDA, reported on 29 August, increasing by 13% y-o-y. The company is benefiting...
Edison issues update on InMed Pharmaceuticals (IN)
September 20, 2018 07:42 ET
|
Edison Investment Research Limited
LONDON, Sept. 20, 2018 (GLOBE NEWSWIRE) -- InMed continues to make progress on its biosynthesis platform, optimizing the genes that lead E. coli to express the cannabinoids and scaling up the...
Edison issues update on ASLAN Pharmaceuticals (ASLN)
September 19, 2018 11:15 ET
|
Edison Investment Research Limited
LONDON, Sept. 19, 2018 (GLOBE NEWSWIRE) -- ASLAN announced it would be amending the protocol for its ongoing Chinese pivotal trial of varlitinib in biliary tract cancer. The patients being enrolled...
Edison issues ADR update on Kazia Therapeutics (KZIA)
September 19, 2018 11:10 ET
|
Edison Investment Research Limited
LONDON, Sept. 19, 2018 (GLOBE NEWSWIRE) -- Kazia Therapeutics has commenced the Phase II program for GDC-0084 in glioblastoma (GDC-0084 was in-licensed from Genentech in 2016). Initial data from the...
Edison issues update on Hutchison China MediTech (HCM)
September 18, 2018 05:33 ET
|
Edison Investment Research Limited
LONDON, Sept. 18, 2018 (GLOBE NEWSWIRE) -- Hutchison China MediTech’s (HCM) lead TKI asset, fruquintinib, has received China registration approval from the National Medical Products Administration...